^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Bladder Cancer
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for HER2 Positive Breast Cancer)
    New
    Title:

    NHS Scotland Grants Trastuzmab Deruxtecan Approval for Use in Pretreated HER2+ Metastatic Breast Cancer

    Excerpt:
    The Scottish Medicines Consortium (SMC) has accepted fam-trastuzumab deruxtecan-nxki (Enhertu) as a treatment option for adult patients with HER2-positive unresectable or metastatic breast cancer who have received 1 prior anti–HER2-based therapy....The advice is based on findings from the pivotal phase 3 DESTINY-Breast03 trial (NCT03529110), in which trastuzumab deruxtecan led to a 12-month progression-free survival (PFS) rate of 75.8%...
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    AACR 2023
    Title:

    472 / 3 - HER2 as a therapeutic target in bladder cancer

    Published date:
    03/15/2023
    Excerpt:
    We also observed a complete response of a HER2+ bladder cancer patient treated with T-DXd (based on PET at 7 weeks)….The greater sensitivity of HER2 altered bladder cancer models to HER2-targeted ADC T-DXd and the complete response to T-DXd in a HER2+ bladder cancer patient...